DOCSLIB.ORG

LONG-TERM MEMBERS 25+ Years of Membership

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
LONG-TERM MEMBERS 25+ Years of Membership LONG-TERM MEMBERS 25+ Years of Membership Stuart A. Aaronson, MD Peter C. Adamson, MD Luisa Airoldi, PhD Francis Ali-Osman, DSc Icahn School of Medicine at Mount Sinai, Sanofi, United States Mario Negri Institute for Duke Univ. Comprehensive Cancer Ctr., United States 31 Years Pharmacological Research, Italy United States 38 Years 29 Years 33 Years Richard H. Adamson, PhD Cory Abate-Shen, PhD TPN Associates, LLC, United States Yukihiro Akao, MD Kari K. Alitalo, MD, PhD Columbia University Irving Medical 57 Years Gifu Univ., Japan University of Helsinki, Finland Center, United States 25 Years 31 Years 26 Years Douglas R. Adkins, MD Washington University School of Hirotoshi Akita, MD, PhD Ayad M. Al-Katib, MD James L. Abbruzzese, MD Medicine, United States Hokkaido Univ. Grad. School of United States Duke University, United States 29 Years Medicine, Japan 33 Years 32 Years 26 Years Samuel Evans Adunyah, PhD Carmen J. Allegra, MD Ehtesham A. Abdi, MBBS Meharry Medical College, United States Shin-ichi Akiyama University of Florida, United States The Tweed Hospital, Australia 32 Years Japan 32 Years 33 Years 28 Years Stefan Aebi, MD Steven L. Allen, MD Kaoru Abe, MD Lucerne Cantonal Hospital, Switzerland Steven A. Akman, MD Northwell Health, United States Yokohama Rosai Hospital, Japan 26 Years Roper St. Francis Healthcare, 27 Years 25 Years United States Rajesh Agarwal, PhD 35 Years Theresa M. Allen, PhD Herbert T. Abelson, MD University of Colorado Denver, Skaggs University of Alberta, Canada United States School of Pharmacy, United States Emmanuel T. Akporiaye, PhD 29 Years 48 Years 30 Years Verana Therapeutics, United States 31 Years Michael C. Alley, PhD Elliot Abemayor, MD, PhD Bharat B. Aggarwal, PhD NCI-Frederick, United States David Geffen School of Medicine at UT MD Anderson Cancer Center, Ala-Eddin Al Moustafa, PhD 36 Years UCLA, United States United States McGill University, Canada 32 Years 28 Years 26 Years David C. Allison, MD, PhD University of Toledo, United States Richard Joel Ablin, PhD Carol Aghajanian, MD Abdul Al Saadi, PhD 33 Years University of Arizona, United States Memorial Sloan Kettering Cancer Center, William Beaumont Hospital, United States 44 Years United States 52 Years D. Craig Allred, MD 27 Years Washington University School of Ross A. Abrams, MD Suresh K. Alahari, PhD Medicine, United States Rush University Medical Center, Irina U. Agoulnik, PhD LSU Health New Orleans, United States 28 Years United States Florida International University, 27 Years 39 Years United States Alex Almasan, PhD 25 Years Moulay A. Alaoui-Jamali, PhD The Cleveland Clinic, United States Tinya J. Abrams, PhD Segal Cancer Ctr., Canada 25 Years Novartis, United States David A. Ahlquist, MD 29 Years 28 Years Mayo Clinic, United States R. Katherine Alpaugh, PhD 25 Years Kathy S. Albain, MD Fox Chase Cancer Center, United States Hernan F. Acevedo, PhD Loyola University Medical Center, 29 Years Allegheny General Hospital, United States Imran Ahmad, PhD United States 44 Years United States 33 Years Muhyi Al-Sarraf, MD 25 Years William Beaumont Hospital, United States Mildred Acevedo-Duncan, PhD Mark R. Albertini, MD 50 Years University of South Florida, Nihal Ahmad, PhD University of Wisconsin Carbone Cancer United States University of Wisconsin-Madison Center, United States Frederick W. Alt, PhD 29 Years School of Medicine and Public Health, 27 Years Boston Children’s Hospital, United States United States 32 Years Stephen P. Ackland, MBBS 25 Years Pierre J. L. Alberto, MD University of Newcastle, Australia, Switzerland Susan E. Alters, DPhil Australia Khalil Ahmed, PhD 42 Years United States 33 Years University of Minnesota, United States 25 Years 25 Years David S. Alberts, MD Edward M. Acton, PhD Univ. of Arizona Cancer Ctr., Enrique Alvarez, DVM United States Tauseef Ahmed, MD United States Kleo Pharmaceuticals, United States 42 Years New York Medical College, United States 46 Years 31 Years 37 Years David J. Adams, PhD Adriana Albini, PhD Ronald David Alvarez, MD Duke University Medical Center, Myung-Ju Ahn, MD, PhD Milan Bicocca University, Italy Vanderbilt University, United States United States Sungkyunkwan University, Samsung 33 Years 25 Years 32 Years Medical Center, Korea, Republic of 26 Years Anthony P. Albino, PhD William L. Alworth, PhD Gregory P. Adams, PhD United States United States Fox Chase Cancer Center, United States Mamoun Ahram, PhD 40 Years 31 Years 29 Years Jordan 25 Years Claudio Marcelo Aldaz, MD Dino Amadori, MD Lucile L. Adams-Campbell, PhD UT MD Anderson Cancer Center, IRST - Istituto Scientifico Romagnolo Georgetown Lombardi Comprehensive Nita Ahuja, MD United States per lo Studio e la Cura dei Tumori, Italy Cancer Ctr., United States Yale University, School of Medicine, 33 Years 28 Years 26 Years United States 25 Years 1 Verena R. Amberger-Murphy, DPhil Karen H. Antman, MD Jean-Pierre Armand Sr., MD Robert Auerbach, PhD Cancer Trials Ireland, Ireland Boston Univ. School of Medicine, Princess Máxima Center for Pediatric University of Wisconsin, United States 26 Years United States Oncology, France 44 Years 40 Years 31 Years Christine B. Ambrosone, PhD Victor H. Auerbach, PhD Roswell Park Comprehensive Cancer Hoda Anton-Culver, PhD Bruce K. Armstrong, MBBS United States Center, United States University of California, Irvine, Univ. of Sydney School of Public Health, 62 Years 28 Years United States Australia 43 Years 29 Years Nelly Auersperg, PhD Stefan Ambs, PhD University of British Columbia, Canada National Cancer Inst., United States Gamil R. Antoun, PhD Deborah K. Armstrong, MD 48 Years 25 Years Duke University Medical Center, Children’s Oncology Group, United United States States Leonard H. Augenlicht, PhD Magid H. Amer, MD 26 Years 31 Years Albert Einstein Cancer Ctr., United States United States 33 Years 41 Years Peter D. Aplan, MD Andrew Arnold, MD NCI-CCR, United States Univ. of Connecticut School of Medicine, David A. August, MD Bruce N. Ames, PhD 30 Years United States Rutgers University, United States Children’s Hospital Oakland Rsch Inst, 29 Years 31 Years United States Frederick R. Appelbaum, MD 44 Years Fred Hutchinson Cancer Research Julia T. Arnold, PhD Hellmut G. Augustin, PhD Center, United States National Cancer Institute, United States University of Heidelberg, Germany Matthew M. Ames, PhD 25 Years 30 Years 33 Years Mayo Clinic College of Medicine and Science, United States Ettore Appella, MD Susanne M. Arnold, MD Faye C. Austin, PhD 42 Years National Cancer Inst., United States University of Kentucky Markey Cancer United States 52 Years Center, United States 34 Years Shantu Amin, PhD 25 Years Penn State Univ. College of Medicine, Gulshan Ara, PhD Steven D. Averbuch, MD United States United States Paul Arnstein, DVM S D Averbuch Consulting, LLC, 36 Years 31 Years California Dept. of Health Svcs., Cancer United States Research Sect., United States 36 Years Christopher I. Amos, PhD Wadih Arap, MD, PhD 46 Years Baylor College of Medicine, United States Rutgers University, United States Vassilios I. Avramis, PhD 33 Years 30 Years Frederick R. Aronson, MD UCLA David Geffen School of Medicine, Maine Ctr. for Cancer Medicine, United States Honnavara N. Ananthaswamy, PhD Jeffrey M. Arbeit, MD United States 37 Years UT MD Anderson Cancer Center, Jeffrey Arbeit Biomedical Consulting, 30 Years United States United States Giuseppe Avvisati, MD, PhD 39 Years 34 Years Carlos L. Arteaga, MD Univ. Campus Bio-Medico di Roma, Italy UT Southwestern Harold C. Simmons 29 Years Kenning M. Anderson, MD, PhD Nadir Arber, MD Comprehensive Cancer Center, Hektoen Institute of Medicine, United Tel Aviv Sourasky Medical Ctr., Israel United States Sanjay Awasthi, MD States 27 Years 32 Years Texas Tech University Health Sciences 43 Years Center, United States Susan G. Arbuck, MD Diane C. Arthur, MD 27 Years Kristin E. Anderson, PhD United States National Cancer Inst., United States University of Minnesota School of Public 34 Years 36 Years David E. Axelrod, PhD Health, United States Rutgers University, United States 29 Years Federico Maria Arcamone, PhD Dave N. T. Aryee, DrRerNat 26 Years Italy St. Anna Children’s Cancer Research Marshall W. Anderson, PhD 36 Years Inst., Austria Ayse Ayhan, MD, PhD Medical College of Wisconsin, 25 Years Seirei Mikatahara General Hospital, United States Michael C. Archer, PhD Japan 39 Years University of Toronto, Canada Fumiki Asanuma, MD 27 Years 40 Years Kitasato Institute Hospital, Japan Paul N. Anderson, MD 29 Years Mohammad Azab, MD Medical Oncology P.C., United States Bach Ardalan, MD Astex Pharmaceuticals, Inc., United States 47 Years University of Miami Sylvester Richard Ascione, MD, PhD 29 Years Comprehensive Cancer Center, Georgetown University Medical Center, Peter M. Anderson, MD, PhD United States United States Janeen R. Azare, PhD The Cleveland Clinic, United States 42 Years 26 Years Pfizer Oncology, United States 32 Years 25 Years Karen C. Arden, PhD Curtis L. Ashendel, PhD Tom Anderson, MD Ludwig Inst. for Cancer Research, Purdue University Center for Cancer Jane Azizkhan-Clifford, PhD United States United States Research, United States Drexel University College of Medicine, 45 Years 27 Years 37 Years United States 26 Years Borje S. Andersson, MD, PhD Pablo Arenaz, PhD David M. Ashley, MBBS, PhD UT MD Anderson Cancer Center, Texas A&M International University Duke University Medical Center, Sadie Aznavoorian-Cheshire, PhD United States (TAMIU), United States United States Franklin W. Olin College of Engineering, 29 Years 36 Years 26 Years United States 28 Years Michael Andreeff, MD, PhD Mary F. Argus, PhD Raghbir S. Athwal, PhD UT MD Anderson Cancer Center, United States Temple University School of Medicine, Hideo Baba, MD, PhD United States 67 Years United States Kumamoto Univ Graduate School of 43 Years 25 Years Medical Sci, Japan Eric A. Ariazi, PhD 32 Years Paul A. Andrews, PhD Freenome, Inc., United States Jessie L-S. Au, PhD Dirigo Nonclinical Consulting, LLC, 28 Years Optimum Therapeutics, LLC, David P.
Load more

Recommended publications
  • To Professor Suzanne Cory AC
    Citation for the Award of the Doctor of Laws (Honoris Causa) to Professor Suzanne Cory AC When Suzanne Cory graduated from the Science Faculty at the University of Melbourne molecular biology was in its infancy. In her enthusiasm for this new science she pursued a PhD in Cambridge at the Medical Research Council’s famed Laboratory of Molecular Biology. Immersed in a culture of discovery, her pioneering PhD studies determined the sequence of a transfer RNA, utilising new technology developed by Fred Sanger, one of the three Nobel Laureates in the institute. After three years’ post‐doctoral work at the University of Geneva, Suzanne Cory returned to Australia with her husband, Jerry Adams, to the Walter and Eliza Hall Institute of Medical Research where they helped to introduce gene‐cloning technology to Australia. Since then, her long association with the Institute, including thirteen years as Director, and with the University of Melbourne, has been instrumental in building the international reputation of both institutions and the strength of the Parkville biomedical research network. Suzanne Cory has made major contributions to advancing the science of immunology, cancer and genetics, in a lifelong dynamic research partnership with Adams. Her work is published widely and cited frequently. The positions held by the many PhD candidates and Post‐Doctoral Fellows she has supervised demonstrate her intergenerational influence in developing scientific leaders for the future. The list of accolades and awards Suzanne Cory has received in recognition of her contributions to science is long and distinguished. She was elected a Fellow of the Australian Academy of Science in 1986 and since has been elected to numerous sister organisations across the globe.
    [Show full text]
  • Robert Wood Johnson Medical School Retired Faculty Association Newsletter
    ROBERT WOOD JOHNSON MEDICAL SCHOOL RETIRED FACULTY ASSOCIATION NEWSLETTER JANUARY 2017 VOLUME X, NO. 1 UPCOMING RFA MEETING IN VITRO FERTILIZATION: AN EMBRYONIC HISTORY “A Robot’s View of Our Ocean Planet” By Eckhard Kemmann, MD When I started my training in Obstetrics- Gynecology at SUNY Downstate-Kings County Hospital in Brooklyn almost five decades ago, infertility was encountered by ten percent of couples, and treatment options were limited and primarily surgical. My teachers and mentors at the institution represented different aspects of the presently evolving field of reproductive medicine. Dr. A. Siegler was a pioneer in tubal surgery and laparoscopy – in the 80s he would introduce laparoscopy to China. Dr. J. R. Jones was an early expert in reproductive hormone research, and Dr. A. Gemzell had come from Sweden where he faced mandatory retirement at the age of 65 and brought his expertise to the United States in the use of ovulation induction. Dr. Gemzell was the first to isolate and use (continued on page 2) Josh Kohut, Ph.D. Associate Professor, Department of Marine TABLE OF CONTENTS PAGE and Coastal Science, Rutgers University Upcoming Meeting 1 InT Vitro Fertilization: An Embryonic History Friday, March 3, 2017 by Eckhard Kemmann, MD 1 Noon – 1:30 p.m. Dean’s Conference Room I See You by Elliot Sultanik, MD, Class of 2016 4 Rutgers Robert Wood Johnson Medical School RWJMS RFA Election Results 5 Piscataway, New Jersey Retired RWJMS Faculty Program to Mentor Medical Students 5 All current and retired faculty, staff, and students Faculty Transition to Retirement Program 6 are welcome to attend.
    [Show full text]
  • Sidney Pestka Sid Died Dec. 22, 2016, Surrounded by Family. The
    Sidney Pestka Sid died Dec. 22, 2016, surrounded by family. The quintessential scientist since adolescence, he had been afflicted with dementia for the last few years of his life. Born in Drobin, Poland, at 21 months of age he moved near family to the Williamsburg neighborhood of Brooklyn, and then at age 8 to Trenton, where he excelled at Trenton Central High School. He received a scholarship to Princeton University, from where he graduated summa cum laude with a B.A. in chemistry. He received his medical degree from the University of Pennsylvania School of Medicine on full scholarship. Afterwards, he worked at the National Institutes of Health in the laboratory of Marshall W. Nirenberg. Sid’s early work on the genetic code, protein synthesis and ribosome function led to Nirenberg’s 1968 Nobel Prize in Physiology or Medicine. In 1969, Sid left the NIH for the Roche Institute of Molecular Biology, where he focused on defining how antibiotics worked and proteins are synthesized and, later, interferons. There he was first to purify interferon alpha and beta; the first to clone mature interferons; and the first to develop a commercialized recombinant biotherapeutic—Roferon A. Sid is known as the "Father of Interferon" for his seminal work on interferon, work that gave birth to a $6 billion dollar market directed at the therapy of hepatitis, multiple sclerosis, cancer, and other diseases that affect mankind. Sid was Emeritus Professor of the Department of Biochemistry and Molecular Biology at Robert Wood Johnson Medical School of Rutgers, The State University of New Jersey, which he joined in 1986 and where he served as Chairman for 25 years.
    [Show full text]
  • Conference Participants
    Conference Participants Frederic G. Barr, M.D., Ph.D. David Livingston, M.D. Department of Pathology and Laboratory Emil Frei Professor of Medicine and Genetics Medicine Dana-Farber Cancer Institute University of Pennsylvania School of Medicine Harvard Medical School Philadelphia, Pennsylvania Boston, Massachusetts Anton Berns, Ph.D. Ahmed Mansouri, Ph.D. Division of Molecular Genetics Department of Molecular and Cellular Biology The Netherlands Cancer Institute Max Planck Institute of Biophysical Chemistry Amsterdam, The Netherlands G6ettingen, Germany Mina J. Bissell, Ph.D. Director, Life Sciences Division Sharon B. Murphy, M.D. Lawrence Berkeley National Laboratory Chief', Division of Hematology/Oncology Berkeley, California Children's Memorial Hospital Professor of Pediatrics Meinrad Busslinger, Ph.D. Northwestern University Medical School Senior Scientist Chicago, Illinois Research Institute of Molecular Pathology University of Vienna Stuart H. Orkiu, M.D. Vienna, Austria Leland Fikes Professor of Pediatric Medicine Mario R. Capecchi, Ph.D. Harvard Medical School Eccles Institute of Human Genetics Boston, Massachusetts University of Utah Bruce A. J. Ponder, Ph.D. Salt Lake City, Utah CRC Professor of Ontology Lewis A. Chodosh, M.D., Ph.D. University of Cambridge Assistant Professor Cambridge, England Department of Molecular and Cellular United Kingdom Engineering Division of Endocrinology, Diabetes and Terry H. Rabbits, Ph.D., F.R.S. Metabolism Medical Research Council Laboratory of University of Pennsylvania School of Medicine Medical Biology Philadelphia, Pennsylvania Joint Head, Division of Protein and Nucleic Acid Chemistry Suzanne Cory, Ph.D., F.A.A., F.R.S. Head, Subdivision of Biology Professor of Medical Biology Cambridge, England The Walter and Eliza Hall Institute of Medical United Kingdom Research Melbourne, Australia Giinter Schiitz, M.D.
    [Show full text]
  • NJ's Top 10 Scientists
    NJ’s Top 10 Scientists here are more than 400,000 scientists and engineers in New Jersey hard at work each day delivering breakthrough medicines and technologies that save lives, improve our quality of life and keep our T economy competitive. With the cooperation of the leading technology trade associations in the state, New Jersey Business magazine is proud to present who we think are the “cream of the crop” in innovation: NJ’s Top 10 Scientists. Through their hard work and dedication, these men and women have made significant contributions to their companies, research institutions and society at large. Whether it is a biotechnology drug that helps fight cancer or AIDS, or a new kind of organic, light-emitting device that is four times more efficient than liquid crystal displays, these and other innovations from the scientists profiled are testaments to the research and development work being conducted in “The Innovative State”. We extend our appreciation to The Healthcare Institute of New Jersey, BioNJ, The New Jersey Research & Development Council, the New Jersey Technology Council and the Chemical Council of New Jersey for their assistance in gathering the nominations. The editors at New Jersey Business selected the final winners based on the impact their work has on society at large. A special recognition is being given to one scientist who, after the judging was completed, announced his retirement. Here, we present the innovators in alphabetical order: SPECIAL RECOGNITION Magid Abou-Gharbia, Ph.D., Senior Vice President and Head (Retired), Chemical and Screening Sciences, Wyeth Drug Discovery and Development, South Brunswick, NJ In October, Magid Abou-Gharbia, Ph.D., retired after 26 years with Wyeth Drug Discovery and Development – but not before leaving his mark in the pharmaceutical industry.
    [Show full text]
  • A-Interferon Structure and Natural Killer Cell Stimulatory Activity1
    [CANCER RESEARCH 50. 5328-5332, September 1, 1990] a-Interferon Structure and Natural Killer Cell Stimulatory Activity1 Bo-Liang Li,2 Xiao-Xia Zhao,3 Xin-Yuan Liu,2 Hyon Suk Kim, Karel Raska, Jr., John R. Ortaldo, Barbara Schwartz, and Sidney Pestka4 Departments of Molecular Genetics and Microbiology [B.-L. L., X-X. Z.. X-Y. L., B. S., S. P.] and Pathology [H. S. A., A'. R.J, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, Sew Jersey 08854, and National Cancer Institute, Frederick Cancer Research Facility, Frederick, Maryland 217011J. R.O.I ABSTRACT chased from New England BioLabs, T4 DNA ligase from International Biotechnologies Inc., polynucleotide kinase and deoxyribonucleotide Expression vectors for human a-interferon (Hu-IFN-a) .11. a site- triphosphates from P-L Biochemicals, and [«-"SjATP and [7-12P]ATP specific mutant |Ser"6]Hu-IFN-aJl, and Hu-IFN-aJ/C or Hu-IFN-aC/ from Amersham Corporation. J hybrids were constructed and expressed in Escherichìacoli. These Oligonucleotide-directed Site-specific Mutagenesis. M13mp8 Rf interferons and others were purified by immunoaffinity chromatography DN A was digested with £coRIand Hindi (Fig. 1) and then precipitated with a monoclonal antibody against human a-interferon. Their antiviral by equal volumes of 13% polyethylene glycol/1.6 M NaCl (9). The activity and ability to stimulate natural killer cell activity were determined precipitate was dissolved in 0.01 M Tris •HCl,pH 7.5-1.0 IHMEDTA) in comparison to several other human interferons. These results provide and ligated to the J689 fragment from the Hu-IFN-aJl gene (1, 10, some insight into structure-activity relationships for stimulating natural 11) under the following conditions: 100 ng of M13mpl8 Rf DNA killer cells and confirm our previous conclusions that antiviral activity vector fragment (EcoRl/Hincl\), 10-40 ng of fragment J689, and 0.9 cannot be used to predict other activities for an individual IFN-a species.
    [Show full text]
  • PHS 398/2590 (Rev. 06/09), Biographical Sketch Format Page
    Program Director/Principal Investigator (Last, First, Middle): BIOGRAPHICAL SKETCH Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. DO NOT EXCEED FOUR PAGES. NAME POSITION TITLE Emine Ercikan Abali Associate Professor of Biochemistry, eRA COMMONS USER NAME (credential, e.g., agency login) Pharmacology and Medicine ABALIEM EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.) INSTITUTION AND LOCATION DEGREE MM/YY FIELD OF STUDY (if applicable) University of Southwestern Louisiana, Lafayette, LA B.Sc. 1982-1986 Chemistry University of Southwestern Louisiana, Lafayette, LA M.S. 1988-1988 Chemistry The Ohio State University, Columbus, OH Ph.D. student 1989-1990 Chemistry Cornell University Graduate School of Medical Ph.D. 1990-1996 Pharmacology Sciences and Memorial Sloan Kettering Cancer Center, New York, NY Memorial Sloan Kettering Cancer Center, NY, NY Postdoc 1996-1998 Molecular Therapeutics Columbia University, NY, NY Postdoc 1998-1999 Biological Sciences (10months) A. Personal Background The overall aim of this project is to use dihydrofolate reductase (DHFR) as a prototype for other NAD(P) binding dehydrogenases to identify novel NAD(P) analogues that specifically target the NADPH binding site of DHFR as potent inhibitors of cancer cells. Specifically, we plan to investigate metabolism of NADPS in cell lines and in xenograft animal and to perform in silico screening of the NADPH binding site to identify potential new inhibitors targeted to DHFR. Lastly, we will determine further characterize the mechanism of action of NADPS in accelerating the degradation of DHFR in order to address development of drug-resistance to this new class of inhibitors.
    [Show full text]
  • 'What's a Nice Girl Like You Doing with a Nobel Prize?' Elizabeth Blackburn, 'Australia's' First Woman Nobel Laureat
    ‘What’s a Nice Girl like you Doing with a Nobel Prize?’ Elizabeth Blackburn, ‘Australia’s’ First Woman Nobel Laureate and Women’s Scientific Leadership Jane Carey Centre for Women’s Studies and Gender Research/Monash Indigenous Centre Monash University, Clayton VIC 3800 [email protected] Abstract: In 2009 Elizabeth Blackburn (along with two of her American colleagues) won the Nobel Prize for Physiology or Medicine, confirming her position as a global scientific leader. She was immediately celebrated as Australia’s first woman Nobel laureate. However, although 2009 was a ‘bumper’ year for women Nobel laureates, with five winners in total, the media coverage soon became highly negative and discouraging. Much discussion focused not on Blackburn’s scientific work but on her gender – the difficulties it was assumed she must have faced individually as a woman scientist, and her wider leadership role in encouraging and supporting other women to overcome these obstacles. In this chapter I suggest the continuing highly negative ways the possibilities for women’s participation and leadership in science are discussed are counterproductive. Journalistic, policy and scholarly discussions of the ‘problem’ of women in science misconstrue the extent of women’s participation in the field and the nature of their experiences. In all these spheres, science continues to be understood and represented as an unhappy place for women to be. This misrepresentation, I argue, undercuts the leadership roles women scientists are seeking. Keywords: Elizabeth Blackburn, women scientists, Australian science, gender and science, Nobel Prize On 5 October 2009 molecular biologist Elizabeth Blackburn received a phone call from Geneva with the news that she, along with her American colleagues Carol Greider and Jack W.
    [Show full text]
  • Extensions of Remarks E1059 HON. NANCY L. JOHNSON HON. FRANK
    June 14, 2002 CONGRESSIONAL RECORD — Extensions of Remarks E1059 HONORING LOUISE BELKIN, FRANK and introduced the ‘‘Invention Convention’’ the now used in the clinic and stimulated the cre- JOSLYN, AND TERRY WERDEN West District School’s Grade 5. She also has ation and development of today’s extensive FOR THEIR OUTSTANDING SERV- given her time as an active member of the biotechnology industry. Dr. Pestka’s achieve- ICE AND DEDICATION TO TEACH- Farmington Education Association, and as a ments are the basis of several U.S. and for- ING AT THE WEST DISTRICT member of curriculum teams for writing, eign patents and interferon is now a major SCHOOL IN FARMINGTON, CON- science and social studies. She currently has product of several U.S. and foreign compa- NECTICUT three students whose parents she also taught nies. The market for interferon is expected to in the Farmington School system. Mrs. exceed $7 billion by 2003. HON. NANCY L. JOHNSON Werden is a dedicated public servant and her In addition to interferon’s commercial im- OF CONNECTICUT influence has been strongly felt throughout pact, there was no general antiviral therapy IN THE HOUSE OF REPRESENTATIVES West District School and the families it serves. available before Dr. Pestka began his work on Her presence within our walls will be greatly interferon; today, interferon is the first and only Thursday, June 13, 2002 missed, as she moves on to teach at Farming- general antiviral therapy. Interferon is used to Mrs. JOHNSON of Connecticut. Mr. Speak- ton’s new 5–6 school. treat hepatitis B and C, diseases that afflict er, I rise today to acknowledge the achieve- These three educators have served on the 300 million people worldwide.
    [Show full text]
  • 2020 Annual Report
    2020 Annual Report Make this cover come alive with augmented reality. Details on inside back cover. Contents The Walter and Eliza Hall Institute About WEHI 1 of Medical Research President’s report 2 Parkville campus 1G Royal Parade Director’s report 3 Parkville Victoria 3052 Australia Telephone: +61 3 9345 2555 WEHI’s new brand launched 4 Bundoora campus 4 Research Avenue Our supporters 10 La Trobe R&D Park Bundoora Victoria 3086 Australia Exceptional science and people 13 Telephone: +61 3 9345 2200 www.wehi.edu.au 2020 graduates 38 WEHIresearch Patents granted in 2020 40 WEHI_research WEHI_research WEHImovies A remarkable place 41 Walter and Eliza Hall Institute Operational overview 42 ABN 12 004 251 423 © The Walter and Eliza Hall Institute Expanding connections with our alumni 45 of Medical Research 2021 Diversity and inclusion 46 Produced by the WEHI’s Communications and Marketing department Working towards reconciliation 48 Director Organisation and governance 49 Douglas J Hilton AO BSc Mon BSc(Hons) PhD Melb FAA FTSE FAHMS WEHI Board 50 Deputy Director, Scientific Strategy WEHI organisation 52 Alan Cowman AC BSc(Hons) Griffith PhD Melb FAA FRS FASM FASP Members of WEHI 54 Chief Operating Officer WEHI supporters 56 Carolyn MacDonald BArts (Journalism) RMIT 2020 Board Subcommittees 58 Chief Financial Officer 2020 Financial Statements 59 Joel Chibert BCom Melb GradDipCA FAICD Financial statements contents 60 Company Secretary Mark Licciardo Statistical summary 94 BBus(Acc) GradDip CSP FGIA FCIS FAICD The year at a glance 98 Honorary
    [Show full text]
  • SPHPM Annual Report 2008 the School of Public Health and Preventive Medicine Is a Leading Centre for Clinical and Population Health Research
    SPHPM Annual Report 2008 The School of Public Health and Preventive Medicine is a leading centre for clinical and population health research. Cover image: PhD student, Lavinia Tran. Contents Overview. 2 2008 SPHPM highlights . 4 New centres, registries and collaborations. 5 Research and education summary . 6 2008 SPHPM organisational structure . 7 Research governance . 8 Awards, prizes and fellowships . 9 Registries . 11 Visitors . 14 Seminars. 17 Short courses . 19 Teaching . 21 SPHPM Doctoral program . 26 Funding sources . 35 Publications . 44 Staff . 63 School of Public Health and Preventive Medicine | 1 Overview The School of Public Health and Preventive Medicine (SPHPM) within the Monash University Faculty of Medicine, Nursing and Health Sciences, is one of the largest Schools of Public Health in the Asia Pacific Region, providing extensive opportunities for education, collaborative research and community engagement. SPHPM Executive Group. Standing, left to right: Professor Peter Cameron, Associate Professor Max de Courten, Professor Brian Oldenburg, Associate Professor Damien Jolley, Professor John McNeil, Professor Helen Keleher, Professor Bob Atkins, Professor Joan Ozanne-Smith, Dr Rob hall, Dr Elizabeth Douglas and Professor Andrew Tonkin. Seated, left to right: Associate Professor Chris Reid, Professor Flavia Cicuttini, Ms Lynda Caldwell, Dr Chris Stevenson, Professor Just Stoelwinder, Professor Robert Burton and Dr Belinda Gabbe. Absent: Dr Helena Teede, Professor Paul O’Brien, Professor Paul Myles, Professor Steven Cordner, Professor Andrew Forbes, Associate Professor Wendy Brown, Dr Anna Peeters, Associate Professor Bebe Loff, Professor Brian Priestly, Dr David Goddard, Professor Henry Krum, Associate Professor Karin Leder, Professor Malcolm Sim, Dr Martha Sinclair, Associate Professor Rory Wolfe, Professor Rachelle Buchbinder, Professor Michael Abramson and Ms Martine Radegonde.
    [Show full text]
  • Suzanne Cory’S Passion in Every Sense
    NEWS Biomedical research has been Suzanne Cory’s passion in every sense. She has worked to decode the genetic mysteries of the immune system and cancer, has rallied her country to invest in its scientific future, and is married to a fellow scientist from her post-doctoral years. Nature Medicine talked to the Director of the Walter and Eliza Hall Institute in Melbourne to find out why her love affair with science hasn’t waned in intensity over four decades. Suzanne Cory Reinvigorated from trekking in one of New stamp on Cory’s life: “It was an environ- vival in tumorigenesis. Together with Zealand’s most challenging mountain ment steeped in scientific passion and rigor Adams and a PhD student, David Vaux, ranges during a rare break from work, Cory —four Nobel laureates and ambitious post- Cory discovered that BCL-2, the oncogene was brimming with enthusiasm. docs from all around the world, hungry for activated by chromosome translocation in Uppermost is excitement about her in- success. It was there that I realized that human follicular lymphoma, had a very volvement in a consortium bidding for the there are no half measures in science — the different mode of action than all previ- Federal Government’s Biotechnology commitment has to be all or nothing.” ously characterized oncogenes. Rather Center of Excellence—the winner will be And it was there that she met fellow scien- than stimulating cell proliferation, BCL-2 announced later this year. Cory and her tist Jerry Adams. They married and em- promotes cell survival. “Nobody then colleagues have the bold vision of estab- barked on a research career together, dreamed that simply stopping a cell from lishing a Therapeutics Development which began with post-docs in Geneva.
    [Show full text]